百奥泰：2025年预亏2.8亿元至3.9亿元

Core Viewpoint - The company Baiotai (688177.SH) expects to reduce its losses in 2025 compared to the previous year, with projected net profit attributable to shareholders ranging from -280 million to -390 million yuan, a reduction in losses by 120 million to 230 million yuan [1] Financial Performance - The company anticipates a net profit attributable to shareholders, excluding non-recurring gains and losses, to be between -380 million and -490 million yuan, reducing losses by 65.61 million to 176 million yuan [1] - The expected operating revenue for the reporting period is between 900 million and 970 million yuan, an increase of 157 million to 227 million yuan compared to the same period last year [1] Market Expansion - The sales of Adalimumab injection (Geleli®) and Tocilizumab injection (Shiruili®) have steadily increased compared to the same period last year, contributing to the company's revenue growth [1] - The company has launched Ustinumab injection (STARJEMZA®) in the U.S., leading to growth in both licensing income and sales revenue [1]